EnteroMedics Receives CE Mark Certification for the Maestro RC System, Allowing Australian Regulatory Application to Move Forward

EnteroMedics ETRM, the sole developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that it has received CE Mark approval of its second generation Maestro RC System for the treatment of obesity using VBLOC vagal blocking therapy. The Maestro RC System, a pacemaker-like device, offers a patient-oriented obesity therapy that affects the physiology of hunger and fullness without forcing punitive, mechanical limits to lifestyle and diet, or requiring surgical alteration of the anatomy. As announced in August 2010, the Company plans to commercialize the Maestro RC System in Australia through an application for approval and listing with the Australian Therapeutic Goods Administration (TGA), a process for which CE Mark approval is a prerequisite. CE Mark is a conformance mark granted by the European Commission and recognized by many nations, including Australia. With CE Mark approval achieved, the Company plans to move forward with its application for TGA approval and once approval is granted, the Company expects first commercial sales of the Maestro System in the second half of 2011.